Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) – Research analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for Oruka Therapeutics in a research report issued on Wednesday, April 29th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.59) per share for the quarter, up from their previous forecast of ($0.65). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.84) EPS and FY2027 earnings at ($2.97) EPS.
Several other research firms have also recently weighed in on ORKA. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Stifel Nicolaus upped their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday. Finally, Barclays upped their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.80.
Oruka Therapeutics Stock Up 0.5%
Shares of ORKA opened at $68.41 on Friday. The business’s 50-day moving average price is $49.57 and its 200-day moving average price is $36.87. Oruka Therapeutics has a twelve month low of $8.91 and a twelve month high of $91.00. The stock has a market cap of $3.43 billion, a PE ratio of -36.78 and a beta of -0.54.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16.
Insider Activity at Oruka Therapeutics
In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at $2,206,887.24. This represents a 17.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 23,765 shares of company stock valued at $1,089,745. 24.69% of the stock is owned by insiders.
Institutional Trading of Oruka Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.
More Oruka Therapeutics News
Here are the key news stories impacting Oruka Therapeutics this week:
- Positive Sentiment: HC Wainwright sharply raised multi-quarter and full‑year EPS forecasts, trimming losses across 2026–2027 and reiterating a “Buy” rating with a $120 price target — a clear analyst vote of confidence that supports upside and reduced downside risk from earlier expected losses. MarketBeat ORKA Analyst Note
- Positive Sentiment: Oruka reported positive Phase 2a results for ORKA‑001 in plaque psoriasis (efficacy/safety readouts), which materially de-risks the lead program and strengthens the company’s clinical narrative — a primary fundamental driver for biotech valuation. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
- Neutral Sentiment: Stifel Nicolaus maintained its Buy rating on ORKA, adding further broker support but without a new price target — reinforces analyst backing but is not new catalyst. Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
- Neutral Sentiment: Oruka and its clinical data are getting wider market attention (features in listicles and a Seeking Alpha slide deck), which can boost retail/institutional interest and trading volume but doesn’t by itself change fundamentals. 5 Small-Cap Stocks That Are On Fire Right Now Seeking Alpha: Interim Results From EVERLAST‑A Study
- Negative Sentiment: Oruka priced an upsized $700M public offering at $72.50/share — proceeds can fund development but the deal represents potential near‑term dilution and selling pressure as shares are distributed, a common negative catalyst for existing holders. Oruka Therapeutics prices upsized $700M public offering at $72.50 per share
Oruka Therapeutics Company Profile
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Further Reading
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
